{"id":59986,"date":"2026-03-30T10:14:17","date_gmt":"2026-03-30T08:14:17","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/03\/30\/systemic-type-i-interferon-blockade-mitigates-insulin-resistance-in-a-preclinical-model-of-psoriasis-valuebishnu-prasad-sinha-purbita-bandopadhyay-md-asmaul-hoque-chinky-shiu-chen-li\/"},"modified":"2026-03-30T10:14:17","modified_gmt":"2026-03-30T08:14:17","slug":"systemic-type-i-interferon-blockade-mitigates-insulin-resistance-in-a-preclinical-model-of-psoriasis-valuebishnu-prasad-sinha-purbita-bandopadhyay-md-asmaul-hoque-chinky-shiu-chen-li","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/03\/30\/systemic-type-i-interferon-blockade-mitigates-insulin-resistance-in-a-preclinical-model-of-psoriasis-valuebishnu-prasad-sinha-purbita-bandopadhyay-md-asmaul-hoque-chinky-shiu-chen-li\/","title":{"rendered":"Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis. [[{&#8220;value&#8221;:&#8221;Bishnu Prasad Sinha, \nPurbita Bandopadhyay, \nMd. Asmaul Hoque, \nChinky Shiu Chen Liu, \nSuravi Mukherjee, \nRanit D&#8217;Rozario, \nShreya Roy, \nRituparna Jana, \nShrestha Pattanayak, \nJafar Sarif, \nDipyaman Ganguly&#8221;}]]"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/onlinelibrary.wiley.com\/cms\/asset\/6e7c0dd3-751b-47f1-a93c-60014c2922ae\/eji70160-gra-0001-m.png\" alt=\"Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis\" \/><\/p>\n<p>A preclinical model of TLR7-agonist-induced psoriasis develops insulin resistance by 3 weeks. Development of this psoriasis-associated insulin resistance can be prevented by systemic blockade of type I interferon signaling. <\/p>\n<p><\/p>\n<h2>ABSTRACT<\/h2>\n<p>Psoriasis is a cutaneous autoimmune disease with worldwide prevalence. In situ activation of skin-infiltrating plasmacytoid dendritic cells (pDCs) leading to local induction of type I interferons (IFNs) is a crucial innate initiation event in psoriasis. Psoriatic patients also have notable susceptibility to the development of metabolic syndrome, especially systemic insulin resistance. Interestingly, a crucial role of systemic and metabolic tissue-restricted induction of type I IFNs is now established in metabolic syndrome. We aimed at exploring whether systemic type I IFN abundance contributes to metabolic derangements in psoriatic patients as well. We developed a preclinical murine model of chronic psoriasis that develops systemic insulin resistance, accompanied by a chronic low-grade systemic inflammation. Then we showed that systemic ablation of type I IFN signaling, using a monoclonal antibody against type I IFN receptor IFNAR1, can mitigate the metabolic dysregulation in this preclinical model of psoriasis-associated insulin resistance. Thus, we report a hitherto unknown role of systemic type I IFN abundance in driving systemic insulin resistance and metabolic dysregulations in psoriasis.<\/p>","protected":false},"excerpt":{"rendered":"<p>A preclinical model of TLR7-agonist-induced psoriasis develops insulin resistance by 3 weeks. Development of this psoriasis-associated insulin resistance can be prevented by systemic blockade of type I interferon signaling. ABSTRACT Psoriasis is a cutaneous autoimmune disease with worldwide prevalence. In situ activation of skin-infiltrating plasmacytoid dendritic cells (pDCs) leading to local induction of type I &#8230; <a title=\"Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis. [[{&#8220;value&#8221;:&#8221;Bishnu Prasad Sinha, \nPurbita Bandopadhyay, \nMd. Asmaul Hoque, \nChinky Shiu Chen Liu, \nSuravi Mukherjee, \nRanit D&#8217;Rozario, \nShreya Roy, \nRituparna Jana, \nShrestha Pattanayak, \nJafar Sarif, \nDipyaman Ganguly&#8221;}]]\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/30\/systemic-type-i-interferon-blockade-mitigates-insulin-resistance-in-a-preclinical-model-of-psoriasis-valuebishnu-prasad-sinha-purbita-bandopadhyay-md-asmaul-hoque-chinky-shiu-chen-li\/\" aria-label=\"Read more about Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis. [[{&#8220;value&#8221;:&#8221;Bishnu Prasad Sinha, \nPurbita Bandopadhyay, \nMd. Asmaul Hoque, \nChinky Shiu Chen Liu, \nSuravi Mukherjee, \nRanit D&#8217;Rozario, \nShreya Roy, \nRituparna Jana, \nShrestha Pattanayak, \nJafar Sarif, \nDipyaman Ganguly&#8221;}]]\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[112,42],"tags":[],"class_list":["post-59986","post","type-post","status-publish","format-standard","hentry","category-european-journal-of-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/59986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=59986"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/59986\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=59986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=59986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=59986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}